→ Masako Nakamura will lead Relyvrio’s march to key regions as Amylyx’s general manager and head of the Asia Pacific and Latin America international markets. Nakamura, the SVP, head of Asia at Alnylam from 2018-21, tackled a similar gig as GM, Asia with Aegerion Pharmaceuticals and had a 10-year career at Genzyme. Canada approved Amylyx’s ALS drug, known in that country as Albrioza, in June 2022, while the FDA gave it the go-ahead in September following an unconventional second adcomm.

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 170,300+ biopharma pros reading Endpoints daily — and it's free.

SIGN UP LOG IN

Mythili Koneru returned to her childhood stomping grounds of New Jersey last Friday to lead the medical operations at Legend Biotech, where she’ll drive the cell therapy maker’s expansion into solid tumors and off-the-shelf options.

Legend will tap into her business development chops, built during a stint at Eli Lilly, as it looks to ink more partnerships on the back of its successful collaboration with Johnson & Johnson‘s Janssen, which helped solidify the biotech as one of the early leaders in cell therapy with the approval of Carvykti.

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 170,300+ biopharma pros reading Endpoints daily — and it's free.

SIGN UP LOG IN

Following a decades-long career in Big Pharma, Kelly Page wanted to use her research and commercial experience to help a small company grow.

Last Tuesday, she started at Arvinas, a Pfizer-partnered biotech looking to harness the body’s protein disposal system to degrade disease-causing proteins. She has taken the role of senior VP and global head of oncology strategy and program leadership, a field that’s motivated her personally since three close relatives were diagnosed with lymphoma in 1999.

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 170,300+ biopharma pros reading Endpoints daily — and it's free.

SIGN UP LOG IN

Jim Mullen is in, by his count, his third or fourth “long, cold winter in biotech investing.” But that’s not stopping the ex-Biogen CEO from finding flickers of light.

Earlier this week, private equity player Advent International announced that Mullen had joined as an operating partner — its term for independent advisors who bring industry experience.

Mullen told Endpoints News in an interview that he’s been doing advising work for a number of private equity firms and enjoyed it.

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 170,300+ biopharma pros reading Endpoints daily — and it's free.

SIGN UP LOG IN